1. Home
  2. FRSH vs RCUS Comparison

FRSH vs RCUS Comparison

Compare FRSH & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshworks Inc.

FRSH

Freshworks Inc.

HOLD

Current Price

$14.99

Market Cap

3.6B

Sector

Technology

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$24.27

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRSH
RCUS
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.2B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
FRSH
RCUS
Price
$14.99
$24.27
Analyst Decision
Buy
Strong Buy
Analyst Count
17
14
Target Price
$14.79
★ $40.00
AVG Volume (30 Days)
★ 6.8M
1.2M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 296.88
N/A
EPS
★ N/A
N/A
Revenue
★ $838,809,000.00
$247,000,000.00
Revenue This Year
$15.05
N/A
Revenue Next Year
$14.19
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 16.43
N/A
52 Week Low
$6.79
$16.41
52 Week High
$14.58
$31.74

Technical Indicators

Market Signals
Indicator
FRSH
RCUS
Relative Strength Index (RSI) 60.60 34.00
Support Level $11.83 $20.13
Resistance Level $14.18 $23.45
Average True Range (ATR) 0.51 1.01
MACD 0.05 -0.14
Stochastic Oscillator 72.33 16.00

Price Performance

Historical Comparison
FRSH
RCUS

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: